Literature DB >> 16354276

An overview of regular dialysis treatment in Japan as of 31 December 2003.

.   

Abstract

A statistical survey of 3750 nationwide dialysis facilities was carried out by the Japanese Society for Dialysis Therapy (JSDT) at the end of 2003, with answers to the questionnaires received from 3717 facilities (99.12%). The population of dialysis patients in Japan at the end of 2003 was 237,710, and the number of dialysis patients per million people was 1862.7. The crude death rate during a 1-year period from the end of 2002 to the end of 2003 was 9.3%. The mean age of patients newly introduced to dialysis was 65.4 years, and the mean age of the entire dialysis population was 62.3 years. The primary diseases in the patients newly introduced to dialysis in 2003 included diabetic nephropathy (41.0% of patients) and chronic glomerulonephritis (29.1% of patients). The mean serum neutral fat concentration for all the dialysis patients was 113.9 +/- 71.7 mg/dL (+/- SD). The mean serum low density lipoprotein (LDL)-cholesterol concentration was 90.8 +/- 30.9 mg/dL. Dialysate calcium concentrations ranging from 3.0 mEq/L to less than 3.5 mEq/L were used for majority of the dialysis patients (55.4%). Among anticoagulants given to the dialysis patients, heparins were the most commonly used in 79.3% of the dialysis patients. The relationship between blood pressure during dialysis and life expectancy for 1 year was analyzed for 43,465 patients who had undergone dialysis three times per week at the end of 2001. Results showed a significantly high mortality risk for patients who had systolic blood pressure of less than 100 mm Hg at the start of dialysis, systolic blood pressure of less than 100 mm Hg at the end of dialysis, and the greatest decrease (lowest) in systolic blood pressure of less than 120 mm Hg during dialysis. Patients who received vasopressor therapy during dialysis had a higher mortality risk than those who received no vasopressor therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16354276     DOI: 10.1111/j.1744-9987.2005.00328.x

Source DB:  PubMed          Journal:  Ther Apher Dial        ISSN: 1744-9979            Impact factor:   1.762


  11 in total

Review 1.  Present status and perspectives of bioartificial kidneys.

Authors:  Akira Saito; Tun Aung; Koji Sekiguchi; Yoshinobu Sato; Duc M Vu; Miho Inagaki; Genta Kanai; Reika Tanaka; Hajime Suzuki; Takatoshi Kakuta
Journal:  J Artif Organs       Date:  2006       Impact factor: 1.731

Review 2.  End-stage renal disease and economic incentives: the International Study of Health Care Organization and Financing (ISHCOF).

Authors:  Avi Dor; Mark V Pauly; Margaret A Eichleay; Philip J Held
Journal:  Int J Health Care Finance Econ       Date:  2007-09

3.  Prognosis of bedridden patients with end-stage renal failure after starting hemodialysis.

Authors:  Kimio Sugaya; Asanori Hokama; Eiri Hayashi; Hidekatsu Naka; Masami Oda; Saori Nishijima; Minoru Miyazato; Sanehiro Hokama; Yoshihide Ogawa
Journal:  Clin Exp Nephrol       Date:  2007-06-28       Impact factor: 2.801

Review 4.  Characteristics of the clinical practice patterns of hemodialysis in Japan in consideration of DOPPS and the NKF/DOQI guidelines.

Authors:  Satoru Kuriyama
Journal:  Clin Exp Nephrol       Date:  2008-01-09       Impact factor: 2.801

5.  Risk factor profiles based on estimated glomerular filtration rate and dipstick proteinuria among participants of the Specific Health Check and Guidance System in Japan 2008.

Authors:  Kunitoshi Iseki; Koichi Asahi; Toshiki Moriyama; Kunihiro Yamagata; Kazuhiko Tsuruya; Hideaki Yoshida; Shoichi Fujimoto; Tsuneo Konta; Issei Kurahashi; Yasuo Ohashi; Tsuyoshi Watanabe
Journal:  Clin Exp Nephrol       Date:  2011-11-08       Impact factor: 2.801

Review 6.  Regulation of parathyroid function in chronic kidney disease (CKD).

Authors:  Masafumi Fukagawa; Shohei Nakanishi; Hideki Fujii; Yasuhiro Hamada; Takaya Abe
Journal:  Clin Exp Nephrol       Date:  2006-09       Impact factor: 2.801

Review 7.  The kidney and bone metabolism: Nephrologists' point of view.

Authors:  Masafumi Fukagawa; Yasuhiro Hamada; Shohei Nakanishi; Motoko Tanaka
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

8.  A huge fecalith associated with dialysis-related gastrointestinal amyloidosis.

Authors:  Takashi Ono; Takefumi Narikiyo; Eiichi Nishida; Taihei Yanagida; Chikao Yasunaga; Masanori Hisaoka; Ikuo Sakino; Shunji Osamura; Masahiko Nakamoto
Journal:  Clin Exp Nephrol       Date:  2007-06-28       Impact factor: 2.801

Review 9.  The organization and financing of end-stage renal disease treatment in Japan.

Authors:  Shunichi Fukuhara; Chikao Yamazaki; Yasuaki Hayashino; Takahiro Higashi; Margaret A Eichleay; Takashi Akiba; Tadao Akizawa; Akira Saito; Friedrich K Port; Kiyoshi Kurokawa
Journal:  Int J Health Care Finance Econ       Date:  2007-09

Review 10.  CKD-MBD: impact on management of kidney disease.

Authors:  Hiroaki Ogata; Fumihiko Koiwa; Eriko Kinugasa; Tadao Akizawa
Journal:  Clin Exp Nephrol       Date:  2007-12-21       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.